- Lonza attains global exclusivity for selling phosphatidylserine (PS) for dietary supplements, medical foods, food and beverages.
- Products will be branded and sold under Lonza name.
- Slated for fourth quarter 2011 launch in USA.
Lonza today announced a global commercial partnership with Lipogen for the exclusive rights to sell phosphatidylserine (PS) and PS-based formulations in dietary supplements, medical foods, and food and beverages under the Lonza name. Lonza intends to roll out launch activities in the USA in the fourth quarter of 2011, and expand to other global regions thereafter.
“Adding PS to our portfolio of branded ingredients directly represents our commitment to provide a diverse line of nutrition products and an array of formulation-friendly technical qualities,” said Michael DeGennaro, Global VP Marketing and Sales Nutrition at Lonza. “PS represents our focus of bringing solutions that meet the needs for cognitive support to our customers.”
“Our current primary goal is to bring high quality and efficacious brain support ingredients to the market” said David Rutenburg, President of Lipogen Ltd. “Lonza’s heritage and commitment to those same goals are well recognized in the nutrition industry. Collaborating our efforts with Lonza will further develop the high potential for PS and the modern PS Plus by meeting the needs of improving cognitive well being worldwide.”
PS, which may reduce the risk of dementia and cognitive dysfunction in the elderly as well as reduce stress and mental fatigue joins Lonza’s portfolio of nutritional ingredients backed by scientific evidence. With age the amount of PS naturally diminishes in our brain creating a need for supplementation. PS is the only cognitive health ingredient in the US which received a qualified health claim from the FDA. Lipogen PS also obtained FDA affirmed GRAS (generally recognized as safe) status.
To learn more about Lonza’s nutrition ingredient portfolio, visit www.LonzaNutrition.com.
Lipogen is one of the world's leading suppliers of phosphatidylserine (PS) and phosphatidic acid (PA). Lipogen holds several patents for the production and usage of PS in the US, EU and China. Lipogen is a privately held company, headquartered in Haifa, Israel. Further information can be found at www.lipogen.co.il
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.
For further information:
Lonza Group Ltd
Head of Corporate Communications
Tel +41 61 316 8798
Fax +41 61 316 9798
Lonza Group Ltd
Tel +41 61 316 8540
Fax +41 61 316 9540
Lonza Group Ltd
Tel +1 201 316 9413
Fax +1 201 696 3533